GLP‑1 boom — India prices tumble
GLP‑1 use in India is surging as generic entrants push monthly prices from roughly ₹8,800–₹10,850 down to about ₹1,300, triggering new government advisories ( ). The government warned of serious side effects — pancreatitis, kidney injury and bowel obstruction — and moved to tighten prescription and promotion rules ( ).
Novo Nordisk’s semaglutide patent in India expired on March 20–21, 2026, clearing the way for more than 50 branded generic versions to enter the market. (ndtv.com)) Major domestic players that announced launches include Sun Pharma, Dr Reddy’s, Zydus Lifesciences, Natco, Lupin, Torrent, Cipla, Biocon and Mankind. (fiercepharma.com)) Sun Pharma priced some weekly semaglutide injections at about ₹750 per week and listed weekly ranges up to roughly ₹2,000 for higher-dose formulations. (cnbc.com)) Dr Reddy’s launched its semaglutide brand Obeda as a pre-filled pen at around ₹4,200 per month, and the company said it plans to pursue separate regulatory approval for weight‑management use while targeting exports to Canada, Turkey and Brazil. (cnbc.com)) Natco disclosed vial pricing from ₹1,290–₹1,750 per month and pen-device pricing of ₹4,000–₹4,500 depending on dose, underscoring large format and device-price differences across brands. (fiercepharma.com)) The central regulator moved before and after the launches: a March 10 advisory banned surrogate advertising for these prescription drugs, and regulators carried out inspections at 49 online‑pharmacy warehouses, wholesalers, retailers and wellness/slimming clinics as enforcement was scaled up. (thehindu.com)) The Health Ministry and CDSCO warned that non‑compliance could lead to licence cancellations, penalties and prosecution, and reiterated that GLP‑1 medicines should be dispensed only on prescriptions from endocrinologists, internal‑medicine specialists and, in specific cases, cardiologists. (thehindu.com))
